Axonics, Inc. operates as a medical technology company. The Company focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation solutions which used to treat patients with overactive bladder, fecal incontinence, andurinary retention. Axonics serves patients worldwide.

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Current Report (Form 8-K | Period ending 2024-04-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Axonics (AXNX US)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Current Report (Form 8-K | Period ending 2024-04-30)

Annual Report (Amendment) (Form 10-K/A | Period ending 2023-12-31)

Current Report (Form 8-K | Period ending 2024-04-03)

Current Report (Form 8-K | Period ending 2024-03-22)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)